Corticosteroid Phobia Negatively Impacts Treatment Adherence in Chronic Hand Eczema, reports research

The purpose of the study was to assess the patient-reported outcomes of TCS, which would influence treatment adherence in chronic hand eczema. Researchers used the TOPICOP scale, which is a tool for measuring corticosteroid phobia, and the Medication Adherence Report Scale, or MARS, for patients to assess their adherence to prescribed treatments.

The study recruited patients from the Danish Skin Cohort diagnosed with CHE. As a whole, 927 patients responded to a questionnaire which contained the TOPICOP scale and MARS. This helped achieve a response rate of 69.2%. The TOPICOP scale assessed levels of corticosteroid fear, and MARS estimated the degree of medication adherence.

There were high levels of corticosteroid phobia with patients with CHE:

• 75.5 percent agreed that TCS would harm their skin completely or almost.

• 48.9 percent agreed that TCS would affect their health in the future

• 36.3 percent of patients said they felt a level of fear relating to TCS. However, the patients did not know of any risks associated with its use.

The study also gained fruitful understandings on adherence to treatment:

• 77.9% of patients always or often stopped TCS treatment as soon as they could, indicating considerable reluctance to continue the therapy for the duration needed.

• 54.8% reported that they always or often delayed initiating their TCS treatment as long as possible and therefore further delayed appropriate management.

• In summary, 38.8% of patients admitted to receiving fewer doses than prescribed, and 54.0% reported they had stopped their treatment at some point during the course of treatment.

The effects were also of statistical significance on a reduction in the adherence to the treatment with increasing levels of corticosteroid phobia (P = .004), and hence it highlights that fear of TCS directly affects the effective management of CHE.

One of its drawbacks was that use of TOPICOP scale was not validated specifically in patients with CHE. It has been commonly used in other dermatological conditions. The accuracy of capturing corticosteroid phobia for the above-mentioned patient population is dubious.

In conclusion, among patients with CHE, corticosteroid phobia exists, and the adherence to treatment is significantly lower. Educating these patients about fears using tailored communication will be the solution for enhancing adherence and, therefore, proper management of CHE.

Reference:

Christensen, M. O., Sieborg, J., Nymand, L. K., Guttman-Yassky, E., Ezzedine, K., Schlapbach, C., Molin, S., Zhang, J., Zachariae, C., Thomsen, S. F., Thyssen, J. P., & Egeberg, A. (2024). Prevalence and clinical impact of topical corticosteroid phobia among patients with chronic hand eczema—Findings from the Danish Skin Cohort. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2024.07.1503